Pharmaceutical compound to boost anti-tumor activity

Selective inhibition and multiple delivery systems. Compound to boost anti-tumor activity that selectively inhibits production of immunosuppressor cells. Because it is selective, the compound does not affect the function of cells responsible for immune response during cancer treatment.

Technological differentials

  • Selective inhibition of immunosuppressor cells
  • Various delivery systems: nanoparticles, viral vectors, antibodies, etc.
  • Catalyzes anti-tumor activity
  • Prevention and treatment of tumors and cancers
DOWNLOAD THE BROCHURE

Readiness Level

TRL 3
Critical function
proof-of-concept.

Intellectual Property

CNPEM
PI BR 10 2020 024609 7
Marcio Chaim Bajgelman | Andrea Johanna Manrique-Rincón

Inquiries and licensing

Technology ID: PI107
inovacao@cnpem.br
+55 19 3512 1174

Sustainable Development Goals

Relacionadas